Diseases & Longevity · File 31

Cirrhosis. The silent terminal fibrosis — and the longevity window operates before.

Cirrhosis causes ~2 million annual deaths globally. Its main etiologies have changed: MASLD/MASH is on the rise, alongside alcohol and viral hepatitis. Cirrhosis is silent until decompensation — ascites, variceal hemorrhage, encephalopathy, hepatocellular carcinoma. Longevity medicine operates before: in non-cirrhotic fibrosis, with FIB-4 screening and elastography in at-risk patients.

Why the intervention window is before cirrhosis

Tirrhosis is the visible consequence of years or decades of sustained hepatic damage. Fibrogenesis progresses silently — F0 (no fibrosis) → F1 → F2 → F3 (advanced fibrosis) → F4 (established cirrhosis). Once cirrhosis is established, management is decompensation containment and, in selected cases, transplant. But in F2-F3, fibrogenesis is potentially reversible with adequate intervention (weight loss in MASH, alcohol cessation, antivirals for viral hepatitis).

Modern screening uses FIB-4 (calculated from age, AST, ALT, platelets) as first step, ELF (Enhanced Liver Fibrosis test) or transient hepatic elastography (FibroScan) as second step. AASLD 2023 and EASL 2024 structure this algorithm in patients with MASLD, significant alcohol consumption, or viral hepatitis. Identifying F3-F4 before decompensation is the hepatic longevity target.

Established cirrhosis is containment. F2-F3 fibrosis is reversible. That difference defines the entire hepatic longevity window.
Annual deaths · global

The global weight, in numbers

Data come from GBD, AASLD, EASL, and etiology meta-analyses. They confirm the magnitude of the problem and the etiology shift toward MASLD.

  • Global burden

    ~2M muertes/año

    Cirrhosis causes approximately 2 million annual deaths globally — ~4% of all mortality. Main etiologies are MASLD/MASH (increasing), alcohol, and viral hepatitis B and C (decreasing due to antiviral treatment).
    — Devarbhavi et al., J Hepatol 2023

  • MASLD/MASH increasing

    Causa creciente

    MASLD/MASH is the fastest-growing cause of cirrhosis and hepatocellular carcinoma — linked to the cardiometabolic cluster. That's why FIB-4 screening in cardiometabolic cluster is modern standard.
    — Younossi et al., Hepatology 2023

  • Fibrosis reversibility

    F2-F3 con intervención

    Hepatic fibrosis F2-F3 is potentially reversible with adequate etiologic intervention — sustained 10%+ weight loss in MASH, alcohol cessation, antivirals in viral hepatitis. Above F4 (cirrhosis), reversibility significantly decreases.
    — Vilar-Gomez et al., Gastroenterology 2015

  • Hepatocellular carcinoma (HCC)

    Cribado en cirrosis

    Cirrhosis is main risk factor for hepatocellular carcinoma. Screening with abdominal ultrasound ± alpha-fetoprotein every 6 months is standard in patients with cirrhosis or advanced fibrosis. Early detection changes therapeutic options (resection, ablation, transplant).
    — AASLD HCC Guidance 2023

Chap. 03 · Hepatic-cardiometabolic

The hepatic-cardiometabolic cluster and comorbidities

Cirrhosis and its antechamber (advanced MASH, MASLD with fibrosis) coexist with amplified cardiometabolic cluster. Integrated approach changes outcomes.

  • Amplified cardiometabolic cluster

    MASH + DM2 + HTA

    MASH coexists with T2D (50-70%), HTN, dyslipidemia, and obesity. CV mortality exceeds hepatic in non-advanced MASH. Addressing the cluster is hepatic and cardiovascular prevention simultaneously.
    — Targher et al., J Hepatol 2016

  • Cirrhotic sarcopenia

    Predictor de mortalidad

    Sarcopenia in cirrhosis is an independent predictor of mortality, hepatic encephalopathy, and worse post-transplant outcome. Specialized nutritional management + adapted exercise are indispensable.
    — Carey et al., Hepatology 2019

  • Mental health

    Depresión + abuso de sustancias

    Cirrhosis is associated with depression, anxiety, and substance abuse — particularly in alcoholic etiology. Structured psychosocial approach and, when applicable, addiction management are integral. Coordination with mental health.
    — Mullish et al., Aliment Pharmacol Ther 2017

  • Economic and social burden

    Sostenida en familia

    Decompensated cirrhosis generates recurrent hospitalizations, sustained family and economic burden, work loss. It's one of the chronic diseases with highest impact on SF-36 PCS and MCS.
    — Younossi et al., Liver Int 2017

What we don't offer — and what we do

Wellness Care does not manage decompensated cirrhosis, hepatocellular carcinoma, or liver transplant. Evacuator paracentesis, varices management, hepatic encephalopathy, HCC surveillance, management of Child-Pugh B/C cirrhosis, and transplant are exclusively the hepatologist's and hospital's responsibility. What we do: early screening of advanced fibrosis (F2-F3) with FIB-4 and elastography, addressing the underlying cardiometabolic cluster, intervention on modifiable etiologies, and coordination with hepatology.

We evaluate patients with: diagnosed MASLD wanting to quantify advanced fibrosis risk, significant alcohol consumption without established hepatic diagnosis, family history of cirrhosis, viral hepatitis B or C under follow-up wanting to optimize the longevity view, or suspected hepatic fibrosis without clear cause. Intervention integrates FIB-4, ELF / elastography when applicable, cluster approach, viral vaccination (HAV, HBV), alcohol reduction, and coordination with hepatology when advanced suspicion.

Established cirrhosis is containment. F2-F3 fibrosis is reversible. Longevity medicine operates in that range — years before decompensation.
How we measure it

How hepatic risk is evaluated
at Wellness Care

FIB-4 + elastography when indicated + cardiometabolic cluster + intervention on modifiable etiologies + coordination with hepatology. That integration changes trajectory.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications — global burden, fibrosis reversibility, MASLD/MASH cluster, cirrhotic sarcopenia.

«La cirrosis causa aproximadamente 2 millones de muertes anuales globalmente, con MASLD/MASH como causa creciente más rápida.»
J Hepatol · 2023
Devarbhavi et al., J Hepatol 2023
Carga global cirrosis
«La pérdida sostenida del 10% del peso corporal puede revertir esteatohepatitis y reducir significativamente la fibrosis hepática.»
Gastroenterology · 2015
Vilar-Gomez et al., 2015
Reversibilidad fibrosis
«La sarcopenia en cirrosis es predictor independiente de mortalidad, encefalopatía hepática y peor desenlace post-trasplante.»
Hepatology · 2019
Carey et al., Hepatology 2019
Sarcopenia cirrótica

Frequently asked questions about cirrhosis

The most recurrent questions about cirrhosis — FIB-4, elastography, MASH, fibrosis reversibility, and why longevity medicine operates in pre-cirrhotic phase.

01

How is FIB-4 calculated and what does it mean?

FIB-4 = (age × AST) / (platelets × √ALT)

It's a validated tool to estimate advanced hepatic fibrosis using routine data.

Interpretation:

· FIB-4 < 1.3 → low advanced fibrosis risk
· 1.3-2.67 → intermediate risk (additional evaluation)
· > 2.67 → high risk (hepatology referral, consider elastography or ELF)

AASLD 2023 and EASL 2024 structure the screening algorithm with FIB-4 as first step.

02

Can cirrhosis be reversed?

Established cirrhosis (F4):

· Very limited reversibility
· Management: decompensation containment
· In selected cases: transplant

F2-F3 fibrosis (before cirrhosis):

· Potentially reversible with adequate etiologic intervention:
  · Sustained 10%+ weight loss in MASH
  · Complete alcohol cessation
  · Antivirals for viral hepatitis

That's the hepatic longevity target: detect F2-F3 before F4 and reverse.

03

How much alcohol is "safe" for the liver?

Modern evidence suggests no safe established level of alcohol exists for the liver.

Hepatic damage risk increases in dose-dependent fashion.

Recent data show even low consumption increases risk of:

· Cancer
· MASLD progression
· Cardiovascular

In patients with:

· MASLD
· Viral hepatitis
· Advanced fibrosis

Recommendation is complete cessation.

Decision with treating physician.

04

When should I consult?

A structured assessment is worthwhile if:

· Diagnosed MASLD and want to quantify fibrosis risk
· Sustained significant alcohol consumption
· Viral hepatitis B or C under follow-up
· Family history of cirrhosis
· Unexplained elevated transaminases
· Unexplained thrombocytopenia
· Detected fatty liver and cardiometabolic cluster

The assessment orients FIB-4 screening and coordination with hepatology — does not replace hepatology when advanced fibrosis or established cirrhosis.

Before decompensation

Established cirrhosis is containment. F2-F3 fibrosis is reversible. Hepatic longevity operates in that window.

Screen with FIB-4, indicate elastography or ELF when applicable, address modifiable etiologies (MASH, alcohol, viral), and coordinate with hepatology — that's real hepatocellular prevention.

Diagnosed MASLD or significant hepatic factor?

Book an advanced hepatometabolic assessment

We evaluate extended hepatic profile (transaminases, GGT, albumin, platelets, INR), FIB-4, ELF or elastography indication when applicable, cluster metabolic profile, alcohol exposure, viral vaccination, and systemic comorbidities. Does not replace hepatology — complements it with the longevity view.

Book advanced hepatometabolic assessment